Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.

@article{Backes2016ProteinprimemodifiedVV,
  title={Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.},
  author={Simone Backes and Clemens Jaeger and Claudia J. Dembek and Anna D. Kosinska and Tanja Bauer and Ann-Sophie Stephan and Andris Di{\vs}lers and George K. Mutwiri and Dirk H Busch and Lorne A. Babiuk and Georg Gasteiger and Ulrike Protzer},
  journal={Vaccine},
  year={2016},
  volume={34 7},
  pages={923-32}
}
BACKGROUND Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. METHODS Modified Vaccinia virus Ankara (MVA) expressing hepatitis B virus (HBV) antigens was used to boost protein-prime vaccinations in wildtype and HBV-transgenic (HBVtg) mice. RESULTS Protein-prime/MVA-boost… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 38 references

induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus ( HBV ) transgenic mice

  • MM Farag, R Tedjokusumo, C Flechtenmacher, T Asen, W Stremmel, M Muller
  • 2013

Similar Papers

Loading similar papers…